Danson, S., Collinson, M., Plummer, E. R., Ottensmeier, C. H., Silva, S., Hook, J., Hapuarachi, B. S., Wheater, M., Payne, M., Oladipo, O., Waterston, A. M., Velikova, G., Gallagher, F. A., Meads, D. M., Bell, S. E., Greatorex, N., Katona, E., Bestall, J., Daniels, S., Corrie, P. G. (2025). Comparison of 1 year versus minimum 2 years of anti-PD1-based immunotherapy as first-line treatment for metastatic melanoma: Results of the DANTE phase III trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.17_suppl.lba9508